THE WHOLE PIPELINE>>>>>>>>>>>>>>>>>>>>>>>>>>>>
We have acquired exclusive rights to several drugs against a number of human diseases. Our current portfolio of product candidates in pre-clinical development include two anti-cancer agents targeting four different tumors (Kevetrin and KM3174); one candidate targeting rheumatoid arthritis (KM277); a small molecule compound with an indication of osteo-arthritis/asthma (KM278); a small molecule compound with an indication of neurological disorders for the treatment of Multiple Sclerosis, Lou Gehrig Disease, and/or Parkinson’s Disease (KM362) a small molecule compound for the treatment of Psoriasis (Prurisol-KM133) and a small molecule compound for the treatment of autism (KM-391).
| Kevetrin | Cancer | Phase 1 |
| Prurisol | Psoriasis | Phase 2/3 505(b)(2) |
| KM 391 | Autism | Preclinical |
| KM 227 | Arthritis | Preclinical |
| KM 278 | Arthritis/Asthma | Preclinical |
| KM 3174 | Cancer | Early R&D |
| KM 362 | MS/ALS/Park | Early R&D |
| KM 732 | Hypertensive emergency | Early R&D |